DOI: 10.5061/dryad.6wwpzgn66
title: Data from: The classical and alternative circulating renin-angiotensin system in normal dogs and dogs with stage B1 and B2 myxomatous mitral valve disease

description: The behavior of the comprehensive circulating renin‐angiotensin system
 (RAS) in dogs with myxomatous mitral valve disease (MMVD) before the onset
 of congestive heart failure remains largely unexplored.
 Hypothesis/Objectives: The classical and alternative RAS activity and
 aldosterone concentrations will be significantly higher in dogs with
 American College of Veterinary Internal Medicine (ACVIM) stage B2 MMVD
 compared to normal dogs and dogs with ACVIM stage B1 MMVD. Animals: One
 hundred seventeen client‐owned dogs (normal = 60; B1 = 31; B2 = 26).
 Methods: Prospective observational study. Angiotensin peptides (AP) and
 aldosterone concentrations were measured using liquid chromatography and
 mass spectrometry. Angiotensin converting enzymes 1 and 2 (ACE, ACE2) and
 renin activity surrogates were calculated from AP concentrations.
 Equilibrium dialysis (ED) and immediate protease inhibition (PI) methods
 of AP quantification were compared in 14 healthy dogs. Results: Core RAS
 activity and aldosterone concentrations did not differ among the 3 groups.
 However, the balance between the alternative and classical RAS differed,
 with dogs with stage B2 MMVD having significantly higher ACE2 activity
 surrogate (ACE2surr) when compared to normal dogs (adjusted P = .02; ratio
 of medians for ACE2surr [B2:normal], 1.89; 95% confidence interval [CI]:
 1.4‐2.6). The ED and PI methods of AP quantification were highly
 correlated (AngI, r = .9, P &lt; .0001; AngII, r = .8, P = .001).
 Conclusions and Clinical Importance: Circulating alternative RAS activity,
 specifically the surrogate measure of ACE2 activity, was increased in dogs
 with stage B2 MMVD as compared to normal dogs. Equilibrium dialysis
 results are analogous to immediate protease inhibition in dogs.
description: Demographic, clinical, and biochemical data were collected
 prospectively during the clinical visit of each patient.  Data were
 entered into an Excel spreadsheet by the study investigators.  These data
 were entered into a commercial statistical software.  The data have not
 been processed. 
description: # The classical and alternative circulating renin-angiotensin system in
 normal dogs and dogs with stage B1 and B2 myxomatous mitral valve disease
 [https://doi.org/10.5061/dryad.6wwpzgn66](https://doi.org/10.5061/dryad.6wwpzgn66) ## Description of the data and file structure **Demographic, physical exam, and biochemical data are included in the files RAAS Project Normal Dogs; RAAS Project B1 Dogs; RAAS Project B2 Dogs** Tabs: Exam_and_history: demographic, physical exam, and historical information; CBC_Chem: complete blood count and serum biochemistry results; Urine: urinalysis results; Echo: echocardiographic data Missing data denoted by an empty cell; Data field that are not applicable to a patient are denoted by N/A or n/a; Date: date of exam; Sex: MI=0, MC=1, FI=2, FS=3; Amount: amount of food fed in cups; Na+%: sodium content of diet; MealToCollectionTime: time between meal and blood collection; BP: blood pressure (mmHg); HR: heart rate (bpm); Demeanor: normal=0, nervous or anxious=1; AM_PM: AM=0, PM=1 ePV: estimated plasma volume; NucCells: total nucleated cell count 10^3/uL; Remainder of abbreviations are standard for serum biochemical, CBC, and urinalysis reporting; UP-C: urine protein to creatinine ratio LAmax-Ao: left atrium to aortic ratio from right parasternal long axis 4 and 5-chamber views; LA-Ao: left atrium to aortic ratio from right parasternal short axis view; LVIDDn: normalized left ventricular dimension in diastole; EF: ejection fraction; FS: shortening fraction (%); TR: tricuspid regurgitation greater than trace (yes or no); PH: pulmonary artery systolic pressure &gt; 35mmHg (yes or no) **Renin-angiotensin-aldosterone system quantification data are included in the file RAAS project AP data** Tabs: normal: angiotensin peptide and aldosterone concentrations for normal dogs; Week 2: subset of dogs returning for a 2nd visit 2 weeks after their initial visit; PI vs. ED: results of protease inhibited vs. equilibrium dialysis methods for angiotensin peptide quantification; B1: angiotensin peptide and aldosterone concentrations for B1 dogs; B2: angiotensin peptide and aldosterone concentrations for B2 dogs; UAldo C: urine aldosterone to creatinine ratios for all dogs Missing data denoted by an empty cell; Data field that are not applicable to a patient are denoted by N/A or n/a; N: normal dogs; B1: dogs with ACVIM Stage B1 myxomatous mitral valve disease; B2: dogs with ACVIM stage B2 myxomatous mitral valve disease; NW2: normal group - week 2 sample; ED: equilibrium dialysis method of sample handling; PI: protease inhibition method of sample handling; UAldo-C: urine aldosterone to creatinine ratio; TimeBtwSamples: time between week 1 and week 2 samples (days) Ang: angiotensin peptides measured in serum (pmol/L); Aldo: aldosterone measured in serum (pmol/L); PRA-S: plasma renin activity surrogate; ACE-S: angiotensin converting enzyme activity surrogate; AA2: aldosterone to angiotensin II ratio; ACE2-S: agiotensin converting enzyme 2 surrogate; ALT: alternative RAS activity surrogate